Cellenkos
Phase 1Cellenkos is a Clinical-Stage Biotechnology Company that is developing Allogeneic, Tissue-Targeted, Immune T-Regulatory Cell Therapies to Treat Autoimmune Diseases & Inflammatory Disorders.
Founded
2016
Focus
Cell & Gene Therapy
About
Cellenkos is a Clinical-Stage Biotechnology Company that is developing Allogeneic, Tissue-Targeted, Immune T-Regulatory Cell Therapies to Treat Autoimmune Diseases & Inflammatory Disorders.
Funding History
3Total raised: $110.5M
Series A$80MRiverVest Venture PartnersFeb 15, 2023
Series A$15.5MKhosla VenturesOct 15, 2021
Seed$15MUndisclosedJun 15, 2021
Company Info
TypePrivate
Founded2016
LocationHouston, United States
StagePhase 1
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile